Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Study sponsor: Iovance Biotherapeutics, Inc. · IOVA
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2030-12Estimated
Enrollment · participants170Estimated
Source updated2026-06-26Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.